Among those with adverse-risk AML and TP53 mutations, median OS was 9.97 months with CPX-351 (n = 4) versus 6.41 months with 7 + 3 (n = 10; Additional file 1: Table S1). This evidence concerns the gene TP53 and acute myeloid leukemia.